Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating three doses of a controlled-release formulation of varenicline for smoking cessation was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• CHANTIX (varenicline tartrate)

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 2 | Status: WITHDRAWN